A popular headlines on the pharma news was CSL Biotherapies award of $1.5billion from the United States Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile
.

Under the terms of the contract, the U.S. Government may request CSL Biotherapies to manufacture and store bulk antigen that can be used against influenza strains with pandemic potential as was further reported in the pharma news.

The contract has a maximum potential value of $1,511,407,737.78 if all optional activities are exercised over the duration of the contract.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Vaccine Partnering Terms and Agreements

Related reports: Influenza Partnering

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more